Scientific Advisory Committee

OUR INTERNATIONAL SCIENTIFIC ADVISORY COMMITTEE

All Breakthrough Cancer Research is assessed by International experts and our own Scientific Advisory Committee, themselves international experts in academia, clinical research, oncology and industry, are involved in Peer Review. Importantly our Scientific Advisory Committee are also involved in the development of our research strategy and in monitoring and assessing whether our research investment is meeting our strategic objectives.

PROF. BRENDAN BUCKLEY PROF. KEVIN HARRINGTON PROF. MICHAEL GOGGINS

(CHAIR)

Chief Medical Officer at Tekro a Clinical trials software company. Prof Buckley, trained as an endocrinolXogist and has over 30 years’ experience in the medical sector. He has been a board member of the Irish Medicines Board and of the European Medical Agency (EMA)’s Scientific Advisory Group for Diabetes and Endocrinology since 2005. Ireland

DR. OWEN O’CONNOR

American Cancer Society Research Professor, Division of Hematology and Oncology and Director, Program for T-Cell Lymphoma Research, E. Couric Cancer Center, University of Virginia Cancer Center. Professor, Department of Microbiology, Immunology, and Cancer Biology, University of Virginia. Chief Scientific Officer, TG Therapeutics. USA Professor of Biological Cancer Therapies at The Institute of Cancer Research and an honorary consultant oncologist at The Royal Marsden. UK

Dr Goggins is a professor of pathology, medicine and oncology at the Johns Hopkins University School of Medicine. He serves as director of the Pancreatic Cancer Early Detection Laboratory and is an attending physician in medicine in the Division of Gastroenterology and Hepatology at The Johns Hopkins Hospital. USA

DR. ALISON O’MAHONY DR. KEVIN HORGAN

Vice President for Recursion, a clinicalstage biotechnology company decoding biology by integrating technological innovations across biology, chemistry, automation, machine learning and engineering to industrialize drug discovery. USA

Protypia. Seasoned physician scientist with executive leadership experience in development of large and small molecules across multiple therapeutic areas with particular expertise in immunology, inflammation and immuno-oncology. USA

“I AM STAGGERED THAT YOU ARE DOING SO MUCH AND THAT YOU ARE ABLE TO DO SO WITH SUCH A LEAN RESEARCH TEAM. IT’S AMAZING.” PROF KEVIN HARRINGTON